JP7284556B2 - Ｔ細胞療法によるエプスタイン－バーウイルス関連リンパ増殖性障害の治療方法 - Google Patents

Ｔ細胞療法によるエプスタイン－バーウイルス関連リンパ増殖性障害の治療方法 Download PDF

Info

Publication number
JP7284556B2
JP7284556B2 JP2017559029A JP2017559029A JP7284556B2 JP 7284556 B2 JP7284556 B2 JP 7284556B2 JP 2017559029 A JP2017559029 A JP 2017559029A JP 2017559029 A JP2017559029 A JP 2017559029A JP 7284556 B2 JP7284556 B2 JP 7284556B2
Authority
JP
Japan
Prior art keywords
ebv
cells
lpd
allogeneic
human patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017559029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520095A (ja
JP2018520095A5 (enExample
Inventor
ジョン オレイリ リチャード
エリザベス プロコプ スーザン
ナスリーン ハサン アイシャ
ドウブロビナ エカテリーナ
Original Assignee
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56027234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7284556(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2018520095A publication Critical patent/JP2018520095A/ja
Publication of JP2018520095A5 publication Critical patent/JP2018520095A5/ja
Priority to JP2021070234A priority Critical patent/JP2021119154A/ja
Application granted granted Critical
Publication of JP7284556B2 publication Critical patent/JP7284556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017559029A 2015-05-12 2016-05-11 Ｔ細胞療法によるエプスタイン－バーウイルス関連リンパ増殖性障害の治療方法 Active JP7284556B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021070234A JP2021119154A (ja) 2015-05-12 2021-04-19 Ｔ細胞療法によるエプスタイン−バーウイルス関連リンパ増殖性障害の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562160549P 2015-05-12 2015-05-12
US62/160,549 2015-05-12
PCT/US2016/031784 WO2016183153A1 (en) 2015-05-12 2016-05-11 Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021070234A Division JP2021119154A (ja) 2015-05-12 2021-04-19 Ｔ細胞療法によるエプスタイン−バーウイルス関連リンパ増殖性障害の治療方法

Publications (3)

Publication Number Publication Date
JP2018520095A JP2018520095A (ja) 2018-07-26
JP2018520095A5 JP2018520095A5 (enExample) 2019-11-14
JP7284556B2 true JP7284556B2 (ja) 2023-05-31

Family

ID=56027234

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017559029A Active JP7284556B2 (ja) 2015-05-12 2016-05-11 Ｔ細胞療法によるエプスタイン－バーウイルス関連リンパ増殖性障害の治療方法
JP2021070234A Pending JP2021119154A (ja) 2015-05-12 2021-04-19 Ｔ細胞療法によるエプスタイン−バーウイルス関連リンパ増殖性障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021070234A Pending JP2021119154A (ja) 2015-05-12 2021-04-19 Ｔ細胞療法によるエプスタイン−バーウイルス関連リンパ増殖性障害の治療方法

Country Status (18)

Country Link
US (1) US10568908B2 (enExample)
EP (1) EP3294304B1 (enExample)
JP (2) JP7284556B2 (enExample)
KR (1) KR102666781B1 (enExample)
CN (3) CN122376731A (enExample)
AR (1) AR104598A1 (enExample)
AU (1) AU2016262484B2 (enExample)
BR (1) BR112017024431B1 (enExample)
CA (1) CA2984178C (enExample)
CL (1) CL2017002846A1 (enExample)
FR (1) FR23C1025I2 (enExample)
IL (1) IL255581B (enExample)
MX (1) MX386334B (enExample)
NZ (1) NZ736675A (enExample)
PH (1) PH12017501993A1 (enExample)
RU (1) RU2720245C2 (enExample)
WO (1) WO2016183153A1 (enExample)
ZA (1) ZA201707335B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3465203B1 (en) 2016-05-25 2026-03-18 The Council of the Queensland Institute of Medical Research Methods of immunotherapy
JP7002769B2 (ja) * 2016-09-16 2022-02-04 ベイラー カレッジ オブ メディスン ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム
EP3700553A1 (en) 2017-10-23 2020-09-02 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
CN108220237B (zh) * 2017-12-20 2020-11-06 中国科学院遗传与发育生物学研究所 一种人的nk/t细胞系
EP3737394A4 (en) * 2018-01-08 2021-11-10 Atara Biotherapeutics, Inc. SYSTEMS AND METHODS FOR DISTRIBUTION OF CELL THERAPIES
EP3765602A1 (en) 2018-03-14 2021-01-20 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
JP2022554217A (ja) * 2019-10-23 2022-12-28 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 養子免疫療法
CN118256604B (zh) * 2024-04-16 2024-11-19 华中科技大学 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US7163685B2 (en) * 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
JP4824389B2 (ja) * 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
WO2010049935A1 (en) 2008-10-30 2010-05-06 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US20140086888A1 (en) 2010-09-01 2014-03-27 Helen E. Heslop Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc)
CA3132353A1 (en) * 2012-05-08 2013-11-14 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
JP2015533366A (ja) * 2012-10-19 2015-11-24 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 改良されたヒトヘルペスウイルス免疫療法
US9907820B2 (en) * 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
EP3215165B1 (en) * 2014-11-05 2020-12-23 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
WO2017003763A1 (en) * 2015-06-27 2017-01-05 Memorial Sloan Kettering Cancer Center Methods of treating glioblastoma multiforme by t cell therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ＧＡＮＤＨＩ Ｍ Ｋ，ＡＭＥＲＩＣＡＮ ＪＯＵＲＮＡＬ ＯＦ ＴＲＡＮＳＰＬＡＮＴＡＴＩＯＮ，２００７年 ５月，ＶＯＬ：７，ＮＲ：５，ＰＡＧＥ（Ｓ）：１２９３ － １２９９，ＵＲＬ，ｈｔｔｐ：／／ｄｘ．ｄｏｉ．ｏｒｇ／１０．１１１１／ｊ．１６００－６１４３．２００７．０１７９６．ｘ
ＨＡＱＵＥ Ｔ，ＴＨＥ ＬＡＮＣＥＴ，英国，ＴＨＥ ＬＡＮＣＥＴ ＰＵＢＬＩＳＨＩＮＧ ＧＲＯＵＰ，２００２年８月１０日，ＶＯＬ：３６０， ＮＲ：９３３１，ＰＡＧＥ（Ｓ）：４３６ － ４４２，ＵＲＬ，ｈｔｔｐ：／／ｄｘ．ｄｏｉ．ｏｒｇ／１０．１０１６／Ｓ０１４０－６７３６（０２）０９６７２－１

Also Published As

Publication number Publication date
EP3294304A1 (en) 2018-03-21
IL255581B (en) 2021-03-25
CN122557727A (zh) 2026-08-14
CL2017002846A1 (es) 2018-05-25
FR23C1025I1 (fr) 2023-07-21
RU2017143151A3 (enExample) 2019-10-29
FR23C1025I2 (fr) 2025-04-18
PH12017501993A1 (en) 2018-03-26
NZ736675A (en) 2023-03-31
BR112017024431B1 (pt) 2021-10-13
RU2720245C2 (ru) 2020-04-28
HK1244697A1 (en) 2018-08-17
AU2016262484B2 (en) 2021-10-21
WO2016183153A1 (en) 2016-11-17
MX2017014257A (es) 2018-04-20
US20180125891A1 (en) 2018-05-10
JP2018520095A (ja) 2018-07-26
BR112017024431A2 (pt) 2018-07-24
ZA201707335B (en) 2021-02-24
KR102666781B1 (ko) 2024-05-20
RU2017143151A (ru) 2019-06-13
CN122376731A (zh) 2026-07-14
AU2016262484A1 (en) 2018-01-04
KR20180003575A (ko) 2018-01-09
CA2984178A1 (en) 2016-11-17
MX386334B (es) 2025-03-18
IL255581A (en) 2018-01-31
CN107835690A (zh) 2018-03-23
US10568908B2 (en) 2020-02-25
JP2021119154A (ja) 2021-08-12
CA2984178C (en) 2023-10-31
AR104598A1 (es) 2017-08-02
EP3294304B1 (en) 2020-01-29

Similar Documents

Publication Publication Date Title
KR102666781B1 (ko) T 세포 요법에 의한 엡스타인-바 바이러스 관련 림프증식성 장애의 치료 방법
EP3490605B1 (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
ES2973832T3 (es) Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
KR20230171451A (ko) 암의 치료를 위한 CD47/SIRPα 결합 및 NEDD8 활성화 효소 E1 조절 서브유닛의 동시저해
TWI759270B (zh) 藉由t細胞療法治療多發性骨髓瘤及漿細胞白血病之方法
HK1244697B (en) Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
WO2017003763A1 (en) Methods of treating glioblastoma multiforme by t cell therapy
EA048183B1 (ru) Комбинированные методы терапии для лечения миелодиспластических синдромов и острого миелоидного лейкоза
HK40008076A (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
HK40008076B (en) Replacement of cytotoxic preconditioning before cellular immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201222

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210420

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221222

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230519

R150 Certificate of patent or registration of utility model

Ref document number: 7284556

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250